Cover Image
市場調查報告書

Serodus ASA:產品平台分析

Serodus ASA - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 293936
出版日期 內容資訊 英文 30 Pages
訂單完成後即時交付
價格
Back to Top
Serodus ASA:產品平台分析 Serodus ASA - Product Pipeline Review - 2015
出版日期: 2015年08月26日 內容資訊: 英文 30 Pages
簡介

Serodus ASA是主要在開發 心血管障礙和代謝性疾病的新治療藥的藥物研發企業。總公司設置於挪威的奧斯陸,並以歐美為首,在日本,中國,印度,巴西皆有發展事業。

本報告提供Serodus ASA 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Serodus ASA的基本資料

  • Serodus ASA概要
  • 主要資訊
  • 企業資料

Serodus ASA:R&D概要

  • 主要的治療範圍

Serodus ASA:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Serodus ASA:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第Ⅱ階段的產品/聯合治療模式
    • 第Ⅰ階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Serodus ASA:藥物簡介

  • SER-100
  • SER-150
  • SER-130
  • SER-140

Serodus ASA:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Serodus ASA:最近的開發平台趨勢

Serodus ASA:暫停中的計劃

Serodus ASA:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • piboserod hydrochloride
    • SER-101

Serodus ASA:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07468CDB

Summary

Global Markets Direct's, 'Serodus ASA - Product Pipeline Review - 2015', provides an overview of the Serodus ASA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Serodus ASA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Serodus ASA including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Serodus ASA's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Serodus ASA's pipeline products

Reasons to buy

  • Evaluate Serodus ASA's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Serodus ASA in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Serodus ASA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Serodus ASA and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Serodus ASA
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Serodus ASA and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Serodus ASA Snapshot
    • Serodus ASA Overview
    • Key Information
    • Key Facts
  • Serodus ASA - Research and Development Overview
    • Key Therapeutic Areas
  • Serodus ASA - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Serodus ASA - Pipeline Products Glance
    • Serodus ASA - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Serodus ASA - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Serodus ASA - Drug Profiles
    • SER-100
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SER-150
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SER-130
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SER-140
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Serodus ASA - Pipeline Analysis
    • Serodus ASA - Pipeline Products by Target
    • Serodus ASA - Pipeline Products by Route of Administration
    • Serodus ASA - Pipeline Products by Molecule Type
    • Serodus ASA - Pipeline Products by Mechanism of Action
  • Serodus ASA - Recent Pipeline Updates
  • Serodus ASA - Dormant Projects
  • Serodus ASA - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • piboserod hydrochloride
      • SER-101
  • Serodus ASA - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Serodus ASA, Key Information
  • Serodus ASA, Key Facts
  • Serodus ASA - Pipeline by Indication, 2015
  • Serodus ASA - Pipeline by Stage of Development, 2015
  • Serodus ASA - Monotherapy Products in Pipeline, 2015
  • Serodus ASA - Phase II, 2015
  • Serodus ASA - Phase I, 2015
  • Serodus ASA - Preclinical, 2015
  • Serodus ASA - Pipeline by Target, 2015
  • Serodus ASA - Pipeline by Route of Administration, 2015
  • Serodus ASA - Pipeline by Molecule Type, 2015
  • Serodus ASA - Pipeline Products by Mechanism of Action, 2015
  • Serodus ASA - Recent Pipeline Updates, 2015
  • Serodus ASA - Dormant Developmental Projects,2015
  • Serodus ASA - Discontinued Pipeline Products, 2015

List of Figures

  • Serodus ASA - Pipeline by Top 10 Indication, 2015
  • Serodus ASA - Pipeline by Stage of Development, 2015
  • Serodus ASA - Monotherapy Products in Pipeline, 2015
  • Serodus ASA - Pipeline by Top 10 Target, 2015
  • Serodus ASA - Pipeline by Top 10 Route of Administration, 2015
  • Serodus ASA - Pipeline by Top 10 Molecule Type, 2015
  • Serodus ASA - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top